Dr Cora Griffin

Q Chip is using a novel approach to encapsulate therapeutic peptides in bioresorbable polymer microspheres for injection and sustained drug release (SR). We avoid the use of harsh solvents, high temperatures and shearing forces and achieve high API loading and microsphere monodispersity- two of the most important desirable features of any encapsulation approach, minimising production cost and enhancing syringe-ability, with controllable burst release. We have recently demonstrated successful sustained release over one month of octreotide, in a preclinical model. A small initial burst release was seen, followed by sustained and essentially zero order octreotide release over at least 35 days. Interestingly, there was no lag phase of octreotide release which might otherwise mandate additional daily injections to achieve therapeutic dosing.

We have had similar success with one and three month SR formulations of leuprolide and intend to go next to POC in man. Our octreotide and leuprolide SR formulations are available for licensing.

We use a similar benign approach to therapeutic protein encapsulation and are collaborating with Artes GmbH on the encapsulation of interferon alpha 2a for SR - targeting an improvement on the weekly shots of pegylated interferon currently taken by hep C sufferers.

Q Chip is developing novel technology platforms for the encapsulation of therapeutic peptides for sustained release (SR) and is committed to demonstrating its platforms' capabilities by producing POC data on SR depot formulations of two market leading therapeutic peptides, leuprolide and octreotide. These depot products will compete in the oncology market and in Q Chip's view represent de-risked opportunities for potential partners since both should be amenable to abbreviated regulatory procedures. We are willing to consider licensing our leuprolide and octreotide formulations and we are also interested in talking to potential partners with peptides in development - there is a clear opportunity to develop new sustained release formulations that may extend product patent life as well as enhancing patient compliance.

Company Type
Dr Cora Griffin
Business Development Manager 

Mr Philippe Grimm

Vitrology Limited provides GMP Bio safety testing services to Bio-pharmaceutical, Biotechnology, Vaccine companies and Academic laboratories.

Company Type
Mr Philippe Grimm

Dr Rob Grundy

Integrated Solutions from Research to Commercialisation.

Almac is a financially secure, privately owned organisation with over 3,300 employees located within the US and UK. Over 600 companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 30+ years.

Our vast range of services include:

Biomarker Discovery & Development: Pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA laboratory. 

API Services & Chemical Development: Services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides.

Pharmaceutical Development:  Developing clinical candidates into an optimum formulation and manufacturing drug product for all phases of clinical trial supply.

Analytical Services: Delivering comprehensive solutions supporting drug substance and product development programmes.

Clinical Trial Supply: Offering over 20 years experience in clinical supply, packaging, distribution and management.

Clinical Technologies: Providing interactive voice and web response technologies, flexible solutions for patient enrollment, electronic PROs and adaptive trials.

Commercial Services: Services for all drug products from manufacturing, testing and packaging to end-user distribution.

 Almac – Partnering to Advance Human Health™

Company Type
Almac Group
Almac Discovery